Chief Business Officer · Arcutis Biotherapeutics, Inc. (ARQT)

Matthew Moore

FY2021 is the first fiscal year CompBrief holds for Matthew Moore as a named executive officer of Arcutis Biotherapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,794,104

Salary $356,704Stock awards $0

3rd of 7 named executive officers at Arcutis Biotherapeutics by FY2021 total.

7 named officers on file for Arcutis Biotherapeutics, FY2021

Matthew Moore’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • ARQT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Arcutis Biotherapeutics’s whole pay program stands against its peers

  • Arcutis Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARQT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2022 (DEF 14A).

Free

Get Matthew Moore’s full pay file as a PDF — free

More than this page: up to 10 years of Matthew’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Matthew Moore compensation by year

Arcutis Biotherapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Arcutis Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$356,704
Bonus$0
Stock awards$0
Option awards$3,234,036
Non-equity incentive$178,352
Pension and deferred compensation$0
All other$25,012
Total$3,794,104

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 19, 2022, accession 0001787306-22-000023, and prior-year filings.

How this page was built: the Arcutis Biotherapeutics, Inc. filed document, accession 0001787306-22-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU25,000$632,100—
Option51,667—$28.72
Option80,000—$28.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Arcutis Biotherapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
John SmitherChief Financial Officer$6,250,292
Todd WatanabePresident and Chief Executive Officer$4,284,123
Matthew Moore · this pageChief Business Officer$3,794,104
Scott BurrowsChief Financial Officer$2,080,377
Patrick BurnettM.D., Ph.D.$1,671,128
Kenneth LockChief Commercial$1,564,381
David OsborneChief Technical Officer$1,555,578

The full Arcutis Biotherapeutics compensation record

free company brief

This page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Arcutis Biotherapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew Moore's compensation dossier · One-time report. No refunds.